Funding for this research was provided by:
Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
Novo Nordisk Fonden (NNF11OC1014333)
Sundhed og Sygdom, Det Frie Forskningsråd (DFF- 4004-00169B)
The research foundation of the Capital Region of Denmark (A4620)
Received: 9 March 2020
Accepted: 19 May 2020
First Online: 27 May 2020
Ethics approval and consent to participate
: The study was approved by the Capital Region’s Committee on Health Research Ethics in Denmark (protocol: ID18024581) and conducted according to the Declaration of Helsinki. Written informed consent was obtained for each participant.
: Not applicable.
: CEC has received personal fees from Teva and serves as a consultant for Teva. FMA has received honoraria from and participate in advisory boards for Novartis, Eli Lilly and Teva. FMA is PI for phase 4 trials for Novartis and Teva. HWS has received speaking fees from Novartis, Lilly and Teva and has received a grant from Novartis. MA has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. MA also participated in clinical trials as the principal investigator for Alder, Amgen, electroCore, Novartis, and Teva. MA also serves as an associate editor of Cephalalgia, associate editor of Headache and co-editor of the Journal of Headache and Pain. MA is President of the International Headache Society, and General Secretary of the European Headache Federation. MA reports research grants from The Lundbeck Foundation, The Research Foundation of the Capital Region of Copenhagen, and The Novo Nordisk Foundation. The other authors declare that there is no conflict of interest.